| INTRODUCTION
Autoimmune diseases may be defined as sustained pathologies in which dysfunctional immune activation results in pathological immune responses that target either cellular or organ-specific selfantigens. Recent studies on the epidemiology of systemic lupus erythematosus (SLE) report that global incidences and prevalences of SLE are increasing. 1 The etiology of the majority of autoimmune diseases remains unknown, many factors including genetics, the microbiome, and environmental toxins could influence or induce autoimmunity and eventually systemic organ disease. [2] [3] [4] All autoimmune diseases are driven by the innate and the adaptive immune response, and disease specificity is often defined by the presence of IgG autoantibodies. 5 Autoantibodies to a large number of selfantigens are usually found in sera of patients with autoimmune diseases. However, in spite of the role played by these antibodies in pathogenesis and progression of autoimmune diseases, their direct role has never been clarified. Therefore, the key to understanding autoimmune diseases with unknown etiology could be in the generation of these autoantibodies.
These pathogenic autoantibodies are produced by plasma cells differentiated from activated autoreactive B cells. In some autoimmune diseases including SLE and rheumatoid arthritis (RA), autoantibodies are usually present several years prior to a diagnosis. 6, 7 Some autoantibodies can be predictive for disease development in asymptomatic subjects. 8 In this study, we detected ANAs associated with specific autoimmune diseases as a basis for developing new diagnostic tools and deepening our understanding of the ANA's role in autoimmune disease. Indirect immunofluorescence (IIF) is still the recommended method for highly sensitive analysis of antibodies using cellular autoantigenic targets. However, in clinical laboratories, ANA detection by IIF analysis has a high false-positive rate. This is particularly true for Sjögren syndrome.
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In our study, the ANA profile (a confirmatory test of ANA) was established by specific immunoblot assay in which test strips were coated with parallel lines of highly purified antigens. For the evaluation of incubated test strips, we used the EUROLineScan software.
Signal intensity can be read after scanning. Outcomes can be used to establish grade and signal intensity for each autoantigen-detecting antibody, and these can be used to classify the ANA profile.
Although the autoantibody response is broad, some ANAs are very specific and can be used as diagnostic criteria in some diseases. 12 Usually, many different autoantibodies can be found in a single sample. To understand the features and clinical significance of these autoantibodies, we investigated 634 cases of autoimmune disease and evaluated the diagnostic efficiency of ANAs in a number of autoimmune diseases including SLE, RA, primary Sjögren syndrome (pSS), and vasculitis. We also evaluated the proportion of specific immunoglobulin (Ig) groups, including M, G, and E to establish whether there were more Ig types in patients with autoimmune disease. 
| METHODS

| Subjects
| Calculation of observed proportion of monospecific ANA (OPM) and theoretical proportion of monospecific ANA (TPM)
Calculation of observed proportion of monospecific ANA OPM = (number of monospecific samples/total number) × 100%
Calculation of theoretical proportion of monospecific ANA Principle: In this test, there were 15 antigens that were random variants; for example, in one sample, if only one antigen was positive and all 14 others were negative, the result was considered monospecific.
In other words, the probability of monospecificity was calculated on the basis of a joint probability: one positive variant and 14 negative variants had to be found in a single sample to qualify as monospecific. According to the principle of probability theory, joint probability is the product of individual probabilities. Theoretically, monospecific probability for an antigen (A) is equal to the product of positive probability of antigen A and negative probability of all other antigens.
, A n is negative probability of antigen A. A n = (number of negative of antigen A/total number) × 100%. The sum of the monospecific probabilities of the 15 autoantigens is theoretical proportion of monospecific ANA.
| Definition of trait ANA
If more than one antigen were found positive in one sample, the IgG with highest ratio was considered as the trait ANA.
14 Ratio = sample signal intensity/control signal intensity.
| Total serum IgE and rheumatoid factor (RF) detection
Total serum IgE and RF were detected by immunonephelometry using the BN II system (Siemens Healthcare Diagnostic Product GmbH, Marburg, Germany).
| Detection of IgG antibodies to hepatitis C virus (HCV) and Treponema pallidum (Syphilis TP assay)
The chemiluminescent microparticle immunoassay (ARCHITECT i2000SR, Abbott Laboratories, Abbott Park, IL, USA) was used for the detection of HCV IgG and Syphilis TP assay. The ARCHITECT iSystem calculates the cutoff (CO) using the mean chemiluminescent signal (RLU). S/CO = Sample RLU/Cutoff RLU. Specimens with S/CO value ≥1.0 were considered reactive.
| Detection of IgG antibody to human immunodeficiency virus (HIV)
ELISA was conducted using diagnostic kit for antibody to HIV detection (Zhuhai Livzon Diagnostics Inc., Zhuhai, China) using an Addcare ELISA 600 immunoassay workstation (Yantai Addcare Bio-Tech Co. Ltd., Yantai, China). Specimens with S/CO value ≥ 1.0 were considered reactive.
| Detection of IgM antibodies to Toxoplasma gondii (Toxoplasma), cytomegalovirus (CMV), and rubella virus (RV)
IgM antibodies to Toxoplasma, CMV, and RV were analyzed using a 
| Statistical analysis
All data were analyzed using SPSS (Statistical Package for Social Sciences) 20.0 software (Chicago, IL, USA). Data were considered to be statistically significant when P < .05. A chi-squared test and nonparametric independent test were used to determine the betweengroup differences in numerical data. Nonparametric binomial tests were used to evaluate OPM and TPM. ROC analysis was carried out to evaluate the diagnostic efficacy for trait ANA. (Table 1) .
| RESULTS
| Results of ANA profile in 643 patients with autoimmune diseases and 61 healthy individuals
| Numbers of ANA (IgG), TPM, and OPM in different autoimmune diseases
The number of positive ANAs (IgG) in one sample was 0-8. The highest number of ANAs (IgG) was 8 in patients with SLE. The highest number of ANAs (IgG) was 5 in patients with RA (Table 2) . If only one IgG ANA was positive, it was called monospecific ANA. The proportions of monospecific ANAs were different in different disease groups (Table 3) . If more than one ANAs were found positive, it was called polyclonal ANA. The proportions of polyclonal ANA were different in different disease groups (Table 3) . TPM was calculated using the formula
for all of the different disease groups. In all groups, the OPM values were lower than the TPM values. Significant differences were found between TPM and OPM in different autoimmune diseases (Table 2 ).
| Results of IgM for Toxoplasma, CMV, and RV, IgG for TP, HCV, and HIV, and total IgE
Results of IgM for Toxoplasma, CMV, and RV, IgG for TP, HCV, and HIV, and total IgE in different autoimmune diseases are in Table 4 .
When the data were analyzed, the P value was <.05 in anti-Toxoplasma IgM group, anti-HCV IgG group, and anti-TP group. However, in antiToxoplasma IgM group, differences were found, when comparing the various disease groups to the control group. In the anti-HCV IgG group and the anti-TP group, differences were only found between the SLE group and control (Table 5 ). The highest RF was 2500 IU/mL.
| Evaluation of diagnostic efficiency
The receiver operating characteristic curve (ROC curve) analyses using the trait ANA as an indicator for the control and autoimmune disease groups are shown in Figure 2 . The area under the curve (AUC) was found to be 0.916 for SLE, while the AUC was found to be 0.646 for RA and 0.830 for other autoimmune diseases.
| DISCUSSION
In this study, the features of ANA (IgG) in autoimmune diseases were analyzed. The definition and calculation method of TPM were proposed using probability theory. In different disease groups (SLE, RA, and other autoimmune diseases), TPM and OPM values were all significantly different (P < .001). OPM values were all lower than were more rare patients in whom monospecific ANAs were found than predicted. On the contrary, polyclonal ANAs which means there were more than one ANA in a single patient were common.
T A B L E 4 Results of IgM for Toxoplasma, CMV, and RV, IgG for TP, HCV, and HIV, and total IgE
Disease Percentiles Compare with control group; none: when the total P value is over .05, comparisons of autoimmune disease group and control group were not made.
Toxoplasma (S/ CO) CMV (S/CO) RV (S/CO) TP (S/CO) HCV (S/CO) HIV (S/CO)
T A B L E 5
Comparison of IgM, IgG, and IgE between autoimmune disease groups and control (P value) F I G U R E 2 Evaluations of diagnostic efficacy for trait ANA in different autoimmune diseases. A, Systemic lupus erythematosus group; B, rheumatoid arthritis group; C, other autoimmune diseases group
In the SLE group, the proportion of polyclonal ANAs was 96.11% (173/180). In the RA group, there was no significance between the proportion of polyclonal ANAs and monospecific ANAs. immunoassays. 17 According to the instructions from the reagent manufacturer, when RF is <3720 IU/mL, there will be no false-positive results in anti-Toxoplasma IgM assays. In this study, RF was detected in all the samples, which were all <3720 IU/mL. This means that it was possible to exclude the false-positive results. In IgG detection, there were significant differences in anti-TP IgG and anti-HCV IgG between different groups, but this difference was only significant between the SLE and control groups. There were no significant differences in IgE detection.
In autoimmune diseases, the elevation of different classes of antibodies suggests that polyclonal antibodies are not limited to IgG.
Other antibodies from IgG and IgM to pathogens for infectious diseases were also affected. We have a hypothesis that more antibodies would be found to increase, if the scope for detection was extended. other studies. 18, 19 In our study, native SSA antigen was purified by affinity chromatography from bovine spleen and thymus. For Ro-52, the corresponding human cDNA has been expressed with the baculovirus system in insect cells. Anti-Ro-52 is a nonspecific autoantibody in the autoimmune diseases including SLE, RA, SS/SLE overlap syndrome, neonatal lupus, and primary biliary cirrhosis. It is not important for the diagnosis and differential diagnosis of autoimmune diseases. However, it has been found that anti-Ro-52
antibody is related to some clinical manifestations and organ lesions. 20, 21 Meaning that it may play an important role in the pathogenesis of autoimmune diseases. Therefore, Ro-52 combined with other autoantibodies could be more meaningful.
In this study, the positive rate of SSA in the SLE group was 53.05%, which was slightly higher than the results reported in the literature.
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The positive rate of SSA in RA was 13.72%, and 44.44% in other groups. Anti-Smith antibody was identified as a specific antibody in the diagnosis of SLE in our study, the positive rate was 16.43%
(35/213). 12, 23 The positive rate of dsDNA, which is another specific antibody in SLE, was 28.64% (61/213). 12, 24 Otherwise, the positive rate of the ANA profile was 84.51% in SLE.
To make full use of an ANA profile and applying it in a diagnostic process, we propose the trait ANA concept, which uses the maximum ratio of signal intensity in immunoblot assays, which can also be interpreted as the highest concentration of autoantibody in samples. The application of the signal intensity is more reliable than grade. For example, in a polyclonal ANA result, there may be several autoantibodies with the same grade but different signal intensity. In order to avoid the batch to batch variations, the ratio between signal intensity and control signal intensity was used to correct. Diagnostic efficiency of trait ANA was evaluated using a ROC curve for the different diseases. For the SLE group, the area under the curve was 0.916, which suggests that this could be an effective laboratory diagnostic indicator. In the other disease groups, the area under the curve is slightly lower than that in the SLE group. The efficiency of this test in the RA group was 0.646, which suggests that trait ANA is not suitable for the diagnosis of RA; this may be related the low polyclonal proportion of ANA panels in this group. 
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